logo-loader
viewComputacenter PLC

Computacenter upgraded to ‘buy’ as Berenberg says firm could outperform their numbers

The bank is assuming the firm will deliver “double-digit organic revenue growth” in its US business, as well as deploying around £150mln in cash through either a share buyback or an acquisition within the next 12 months

computer

Computacenter plc (LON:CCC) has been upgraded by analysts at Berenberg to ‘buy’ from ‘hold’ as the German bank said the company had “scope to outperform” their forecasts in the coming year.

In a note that also raised the IT firm’s target price to 2,150p from 1,500p, Berenberg said they had downgraded the firm “too early” and were now “more confident about the company’s long-run growth outlook”.

READ: Computacenter hails “best ever” year

“The US business has turned a corner, Germany remains very strong and the UK is making margin progress. Heading into next year, structural tailwinds look set to persist and the early attempts at cross-selling between the US and European businesses should improve”, Berenberg said.

Analysts also highlighted that the company’s guidance of a 3% compound annual growth rate in earnings per share was “notoriously conservative” and they believed that there was upside to the numbers.

The bank added that they had assumed the firm will deliver “double-digit organic revenue growth” in its US business, as well as the deployment of around £150mln in cash through either a share buyback at 1,800p each or an acquisition within the next 12 months.

“We just cannot envisage a scenario in which management will hold on to its cash position much longer”, Berenberg said.

The upward revision follows a strong trading update from Computacenter last week, when the firm hailed what it said was one of its “most successful years” in 2019, with both revenue and profits reaching their “best ever” levels.

The shares were lifted 1.3% to 1,815p in late-morning trading on Monday.

Quick facts: Computacenter PLC

Price: 1408 GBX

LSE:CCC
Market: LSE
Market Cap: £1.61 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

1 day, 1 hour ago

2 min read